In conclusion, it would be important to evaluate the efficacy of Ruxolitinib in ENZ-resistant PC with a selection of patients for accrual based on a positive Jak2-Stat5 activation status in PC. This evidence concerns the gene STAT5B and pachyonychia congenita.